



PHARMACYTE BIOTECH, INC.

PMCB May Be On The Verge Of A Major Breakthrough In Diabetes Treatment

Rob Goldman
rob@goldmanresearch.com

November 3, 2015

PHARMACYTE BIOTECH, INC. (OTCQB – PMCB – \$0.1085)

NT Price Target: \$0.45, LT Price Target \$1.80

Rating: Speculative Buy

COMPANY SNAPSHOT

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box®. This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer, and diabetes are being built.

KEY STATISTICS

Price as of 11/2/15	\$0.1085
52 Week High – Low	\$0.27 - \$0.069
Est. Shares Outstanding	743.4M
Market Capitalization	\$80.6M
3 Mo Avg. Vol.	1,755,000
Exchange	OTCQB

COMPANY INFORMATION

PharmaCyte Biotech, Inc.
 12510 Prosperity Drive, Suite 310
 Silver Spring MD 20904

Website: <http://www.PharmaCyte.com>
 Phone: 917.595.2850
 Email: info@PharmaCyte.com

INVESTMENT HIGHLIGHTS

Conclusion: Last week, PharmaCyte held the 2nd annual meeting of its International Diabetes Consortium to review data that has been generated by the Consortium and update its strategic plan for the development of PMCB's treatment for insulin dependent diabetes. With the review now complete we believe management will soon provide investors with a R&D roadmap for its diabetes treatment, taking the stock past a key daily moving average (DMA.)

Game Changing Approach to Type 1 Diabetes Treatment. The two key components of PharmaCyte's treatment for Type 1 diabetes are Melligen cells and the Cell-in-a-Box® technology. Melligen cells have been genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body. PharmaCyte's plan is to encapsulate those live cells and then implant the capsules into a patient with diabetes to act as an "artificial" pancreas, thereby eliminating the need for insulin injections.

No Time Like the Present. The Company's approach could ultimately become a treatment that has clear advantages over current therapies used for Type 1 diabetes, and could potentially replace them. Therefore with November serving as Diabetes Awareness Month, an update on its diabetes research progress will draw substantial attention from major players and funders in diabetes research.

A Better Replacement Thera[ly Serving a Huge Market Adds Up to Huge Potential Increase in Value. In our view, demonstrating the ability to eliminate the need for insulin injections for millions of sufferers through soon-to-be launched next stage studies could be the driver to take these shares to a new 52 week high. Thus, we rate these shares Speculative Buy and reiterate our near term price target of \$0.45 and a long term target price of \$1.80.

RECENT TRADING HISTORY FOR PHARMACYTE BIOTECH, INC.

(Source: www.Stockta.com)



SENIOR ANALYST: ROBERT GOLDMAN

Rob Goldman founded Goldman Small Cap Research in 2009 and has over 20 years of investment and company research experience as a senior research analyst and as a portfolio and mutual fund manager. During his tenure as a sell side analyst, Rob was a senior member of Piper Jaffray's Technology and Communications teams. Prior to joining Piper, Rob led Josephthal & Co.'s Washington-based Emerging Growth Research Group. In addition to his sell-side experience Rob served as Chief Investment Officer of a boutique investment management firm and Blue and White Investment Management, where he managed Small Cap Growth portfolios and *The Blue and White Fund*.

Analyst Certification

I, Robert Goldman, hereby certify that the view expressed in this research report or article, accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report.

Disclaimer

This Opportunity Research report was prepared for informational purposes only.

Goldman Small Cap Research, (a division of Two Triangle Consulting Group, LLC) produces research via two formats: *Goldman Select Research* and *Goldman Opportunity Research*. The *Select* format reflects the Firm's internally generated stock ideas along with economic and stock market outlooks. *Opportunity Research* reports, updates and Microcap Hot Topics articles reflect sponsored (paid) research but can also include non-sponsored microcap research ideas that typically carry greater risks than those stocks covered in the *Select Research* category. It is important to note that while we may track performance separately, we utilize many of the same coverage criteria in determining coverage of all stocks in both research formats. Research reports on profiled stocks in the *Opportunity Research* format typically have a higher risk profile, and may offer greater upside. In 2015, *Goldman Small Cap Research* has been compensated by a third party in the amount of \$22,000 for a research subscription service including reports, updates, and a series of articles. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. *Goldman Small Cap Research* did not make an independent investigation or inquiry as to the accuracy of any information published by the Company, or other firms. *Goldman Small Cap Research* relied solely upon information published by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

Separate from the factual content of our articles about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Such information and the opinions expressed are subject to change without notice.

A *Goldman Small Cap Research* report or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. This publication does not take into account the investment objectives, financial situation, or particular needs of any particular person. This publication does not provide all information material to an investor's decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither *Goldman Small Cap Research*, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA, the U.S. Securities and Exchange Commission or with any state securities regulatory authority.

ALL INFORMATION IN THIS REPORT IS PROVIDED "AS IS" WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com